Origami Therapeutics enters global collaboration with Ipsen
They advance a small-molecule protein degrader for a rare neurodegenerative disorder using ORICISION™ technology.
See the latest news and media coverage for Origami Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of protein degraders and correctors
origamitherapeutics.comLast updated
In short: Origami Therapeutics established a major global collaboration with Ipsen and won recognition at the 2024 BioChallenge.
They advance a small-molecule protein degrader for a rare neurodegenerative disorder using ORICISION™ technology.
Ipsen obtains exclusive option to license Origami's protein degrader program for a rare neurodegenerative disorder. Ipsen would handle global development upon exercising the option.
The company is named a prize winner at the New Orleans BioInnovation Center 2024 BioChallenge. It feels proud and inspired to strive for patients.
Announced on February 8, 2024. Links to information about Y Combinator funded companies.
Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement...
Track Origami Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.